25 The dose of 375 mg/m was selected for further clinical trials in patients with FL or indolent, relapsed B-cell lymphoma.
To test for orientation biases ( = first head turns towards a playback stimulus), we selected for further analyses all trials in which the head criterion ( = the subject was licking on the nipple of the bottle while keeping its head straight and its hands on the wooden bar) was fulfilled.
All trials selected for further review from the Clinical Trials Registry were independently searched using MEDLINE and Google for published results.
Based on the results of these earlier efficacy and safety studies, a dose of 50 μg OD was selected for further clinical evaluation in Phase III trials.
Based on these considerations, five concepts of interest were selected for further investigation within publications of clinical trials with CHC patients that included PRO measurement and publications of PRO development and psychometric evaluation studies.
Two representative steps were selected in 1 trial and a total 12 steps in a subject was selected for further data averaging (2 steps × 6 trials).
Radezolid was selected for further advancement with two phase 2 clinical trials completed to date: the first in CAP and the second trial in cSSSI [ 75].
On the basis of these probabilities along with safety considerations, tofacitinib 5 and 10 mg b.i.d. were selected for further testing in confirmatory phase III clinical trials.
